Product datasheet Anti-AKT2 (Phospho-S474) Antibody Catalog Number: P00725



Building C21, 3rd to 5th Floors, Optics Valley Biopharmaceutical Accelerator, East Lake High-Tech Development Zone, Wuhan.

Web: www.boster.com Phone: 027-67845390/1/2 Email: boster@boster.com

Basic Inform	ation	
Product Name	Anti-AKT2 (Phospho-S474) Antibody	
Gene Name	AKT2	
Source	Rabbit	
Clonality	Polyclonal	
Isotype	IgG	
Species Reactivity	human, mouse, rat	
Tested Application	WB, IHC, ICC/IF	
Contents	500 ug/ml antibody with PBS, 0.02% NaN3, 1 mg/ml BSA and 50% glycerol.	
Immunogen	A synthesized peptide derived from human Akt2 around the phosphorylation site of Ser474.	
Concentration	500 ug/ml	
Purification	Immunogen affinity purified.	
Observed MW	60 kDa	
Dilution Ratios	Western blot (WB): Immunohistochemistry (IHC): Immunocytochemistry/Immunofluorescence (ICC/IF): (Boiling the paraffin sections in 10mM citrate buffer,pH6.0 20 mins is required for the staining of formalin/paraffin se dilutions must be determined by end user.	

Storage

12 months from date of receipt, -20°C as supplied. 6 months 2 to 8°C after reconstitution. Avoid repeated freezing and thawing.

Background Information

AKT2 is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains. This gene is mapped to 19q13.2. AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. AKT2 seems also to be the principal isoform responsible of the regulation of glucose uptake. AKT2 is also specifically involved in skeletal muscle differentiation, one

Product datasheet

Anti-AKT2 (Phospho-S474) Antibody

Catalog Number: P00725



Building C21, 3rd to 5th Floors, Optics Valley Biopharmaceutical Accelerator, East Lake High-Tech Development Zone, Wuhan.

Web: www.boster.com Phone: 027-67845390/1/2 Email: boster@boster.com

of its substrates in this process being ANKRD2. Overexpression of AKT2 contributes to the malignant phenotype of a subset of human ductal pancreatic cancers.

Selected Validation Data

暂无图片